National Academies Press: OpenBook
« Previous: Appendix A: Types of Childhood Cancer
Suggested Citation:"References." Institute of Medicine and National Research Council. 2005. Making Better Drugs for Children with Cancer. Washington, DC: The National Academies Press. doi: 10.17226/11259.
×

REFERENCES

American Cancer Society. 2004. Cancer Facts and Figures, 2004. Atlanta, GA: American Cancer Society.


Bumol TF, Watanabe AM. 2001. Genetic information, genomic technologies, and the future of drug discovery. JAMA 285(5):551–555.

Butte AJ, Tamayo P, Slonim D, Golub TR, Kohane IS. 2000. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc Natl Acad Sci U S A 97(22):12182–12186.


Connors T. 1996. Anticancer drug development: The way forward. Oncologist 1(3):180–181.


Eisenhauer EA. 1998. Phase I and II trials of novel anti-cancer agents: Endpoints, efficacy and existentialism. The Michel Clavel lecture, held at the 10th NCI-EORTC Conference on New Drugs in Cancer Therapy, Amsterdam, Holland, June 16–19, 1998. Annals of Oncology 9(10):1047–1052.


Hollingshead MG, Alley MC, Camalier RF, Abbott BJ, Mayo JG, Malspeis L, Grever MR. 1995. In vivo cultivation of tumor cells in hollow fibers. Life Sciences 57(2):131–141.

Houghton PJ, Stewart CF, Thompson J, Santana VM, Furman WL, Friedman HS. 1998. Preclinical and clinical results with irinotecan: Extending principles learned in model systems to clinical trials design. Oncology 12(8 Suppl.): 84–93.


IOM (Institute of Medicine). 2000. Rational Therapeutics for Infants and Children: Workshop Summary. Washington, DC: National Academy Press.

IOM. 2003. Child Cancer Survivorship: Improving Care and Quality of Life. Washington, DC: The National Academies Press.

IOM. 2004. The Ethical Conduct of Clinical Research Involving Children. Washington, DC: The National Academies Press.


Jemal A, Clegg LX, Ward E, Ries LAG, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN, Edwards BK. 2004. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer 101(1):3–27.


Kerbel RS. 1998/99. What is the optimal rodent model for anti-tumor drug testing? Cancer & Metastasis Reviews 17(3):301–304.


Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. 2000. Proteasome inhibition measurements: Clinical application. Clin Chem 46(5):673–683.


Minino AM, Smith BL. 2001. Deaths: Preliminary data for 2000. National Vital Statistics Reports 49(12):1–40.


National Cancer Institute. 2004. PDQ® Cancer Information Summaries: Pediatric Treatment. Available: http://www.nci.nih.gov/cancerinfo/pdq/pediatrictreatment [accessed December 2004].


Pearce HL. 1995. Anticancer drug development at Lilly Research Laboratories. Annals of Oncology 6(Suppl. 1):S55–S62.

Pediatric AIDS Foundation. Children’s groups appeal pediatric drug testing decision. Pediatric AIDS Foundation News December 16, 2002. Available: http://www.pedaids.org/december16_2002_release.html [accessed February 17, 2005].

Pervan M, Pajonk F, Sun JR, Withers HR, McBride WH. 2001. Molecular pathways that modify tumor radiation response. American Journal of Clinical Oncology 24(5):481–485.

PhRMA (Pharmaceutical Research and Manufacturers of America). 2004. Medicines in Development for Children 2004. Washington, DC: PhRMA.

Phillips RM, Pearce J, Loadman PM, Bibby MC, Cooper PA, Swaine DJ, Double JA. 1998. Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: Implications for anticancer drug screening programs. Cancer Res 58(23):5263–5266.

Suggested Citation:"References." Institute of Medicine and National Research Council. 2005. Making Better Drugs for Children with Cancer. Washington, DC: The National Academies Press. doi: 10.17226/11259.
×

Pizzo PA, Poplack DG, eds. 2001. Principles and Practice of Pediatric Oncology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins.

Powell DA, Nahata MC. 1982. Chloramphenicol: New perspectives on an old drug. Drug Intelligence & Clinical Pharmacy 16(4):295–300.


Reis BY, Butte AS, Kohane IS. 2001. Extracting knowledge from dynamics in gene expression. J Biomed Inform 34(1):15–27.

Ries LAG, Eisner MP, Kosary CL, et al. 2002. SEER Cancer Statistics Review, 1973–1999. Bethesda, MD: National Cancer Institute.


Smith A. 2002. Screening for drug discovery: The leading question. Nature 418(6896):453–459.


U.S. Cancer Statistics Working Group. 2004. United States Cancer Statistics: 2001 Incidence and Mortality. Atlanta, GA: Centers for Disease Control and Prevention and National Cancer Institute.

U.S. District Court for the District of Columbia. 2002. Association of American Physicians and Surgeons, Inc., et al., Plaintiffs, v. United States Food and Drug Administration, et al., Defendants, Civil Action 00-02898 (HHK). Memorandum Opinion. October 17, 2002. Available: http://www.dcd.uscourts.gov/00-02898.pdf.

U.S. Food and Drug Administration. 2004. What’s New by Date. [Online]. Available: http://www.fda.gov/cder/whatsnew.htm [accessed January 5, 2005].

U.S. Food and Drug Administration. 2005. Pediatric exclusivity statistics as of January 31, 2005. Available: http://www.fda.gov/cder/pediatric/wrstats.htm [accessed February 17, 2005].


Von Hoff DD. 1998. There are no bad anticancer agents, only bad clinical trial designs—twenty-first Richard and Hinda Rosenthal Foundation award lecture. Clinical Cancer Research 4(5):1079–1086.

Suggested Citation:"References." Institute of Medicine and National Research Council. 2005. Making Better Drugs for Children with Cancer. Washington, DC: The National Academies Press. doi: 10.17226/11259.
×
Page 41
Suggested Citation:"References." Institute of Medicine and National Research Council. 2005. Making Better Drugs for Children with Cancer. Washington, DC: The National Academies Press. doi: 10.17226/11259.
×
Page 42
Making Better Drugs for Children with Cancer Get This Book
×
Buy Paperback | $29.00 Buy Ebook | $23.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The successes that have been achieved in treating childhood cancers stand as beacons against the less dramatic improvements for adults with cancer. Progress began to accelerate in the 1960s and 1970s, as treatment regimens were built up, primarily by building combinations of chemotherapeutic drugs. However the near absence of research in pediatric cancer drug discovery threatens to halt the progress in childhood cancer treatment achieved during the past four decades. Making Better Drugs for Children with Cancer identifies the major issues to be addressed in developing new agents for childhood cancers, the gaps in research and development, and the steps that have been suggested to move the process forward. This report also makes a new proposal to capitalize on today's science to bring new treatments to children's cancers.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!